Rocket Pharmaceuticals (RCKT) Income towards Parent Company (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Income towards Parent Company data on file, last reported at -$48.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 23.14% year-over-year to -$48.8 million; the trailing twelve-month figure through Mar 2026 stood at -$310.0 million (down 16.75% YoY), and the FY2025 full-year result was -$361.6 million, up 8.22% from the prior year.
• Income towards Parent Company declined to -$48.8 million in Q1 2026, from -$43.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$43.7 million in Q4 2025 to a low of -$190.8 million in Q3 2023.
• A 5-year average of -$100.4 million and a median of -$71.9 million in 2024 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company soared 67.35% in 2022 and sank 64.86% in 2025, its largest moves.
• Tracing RCKT's Income towards Parent Company over 5 years: stood at -$68.3 million in 2022, then grew by 7.86% to -$62.9 million in 2023, then grew by 2.2% to -$61.6 million in 2024, then grew by 28.93% to -$43.7 million in 2025, then decreased by 11.61% to -$48.8 million in 2026.
• Business Quant data shows RCKT's Income towards Parent Company at -$48.8 million in Q1 2026, -$43.7 million in Q4 2025, and -$98.9 million in Q3 2025.